ICD-10

October 1, 2015 marked the compliance date established by the U.S. Department of Health & Human Services (HHS) for health care providers, health plans and health care clearinghouses to transition to the 10th revision of The International Classification of Diseases (ICD-10) Coding System. ICD-10 codes, which are based on three to seven letters and numbers, offer more extensive classification options than the previous ICD-9 codes to establish the medical necessity for all laboratory tests performed and submitted for payment.

ICD-10 RESOURCES:
- American Medical Association (AMA)
- Center for Medicare & Medicaid Services (CMS)
- American Health Information Management Association (AHIMA)
- Healthcare Information and Management Systems (HIMSS)

New 2015 CDC Treatment Guidelines

June 2015 marked the release of updated treatment guidelines for sexually transmitted infections (STD) from the Centers for Disease Control and Prevention (CDC). The new guidelines which update previous guidelines last released in 2010 discuss:

- Alternative treatment regimens for Neisseria gonorrhoeae.
- The use of nucleic acid amplification tests for the diagnosis of trichomoniasis.
- Alternative treatment options for genital warts.
- The role of Mycoplasma genitalium in urethritis/cervicitis and treatment-related implications.
- Updated HPV vaccine recommendations and counseling messages.
- The management of persons who are transgener.
- Annual testing for hepatitis C in persons with HIV infection.
- Updated recommendations for diagnostic evaluation of urethritis.
- Retesting to detect repeat infection.

Physicians and other health-care providers can use these guidelines to assist in the prevention and treatment of STDs. Complete guidelines can be viewed online at www.cdc.gov/std/treatment.

To obtain a copy of MLD's Summary of Treatment Guidelines booklet which is based on the Summary of 2015 CDC Treatment Guidelines (CS253348), please contact MLD's graphics group via email at graphics@mdlab.com.
In the last year, MDL was proud to release many innovative tests and newly validated specimen sources. In order to take full advantage of the tests available, clients are encouraged to update their Electronic Medical Record (EMR) systems with the information below.

### New Tests Released in 2015

<table>
<thead>
<tr>
<th>Test No.</th>
<th>Test Name</th>
<th>Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1221</td>
<td>BRCA1/2 3-site Mutation Analysis (BRCA1/2) Mouthwash</td>
<td></td>
</tr>
<tr>
<td>1222</td>
<td>BRCA1/2 3-site Mutation Analysis with Deletion/Duplication Analysis Mouthwash</td>
<td></td>
</tr>
<tr>
<td>1223</td>
<td>BRCA1/2 3-site Mutation Analysis (Reflex to Comprehensive BRCA Analysis) Mouthwash</td>
<td></td>
</tr>
</tbody>
</table>

**BRCA1/2**: Ashkenazi Jewish 3-site Mutation Analysis
- *If the Ashkenazi Jewish 3-site Mutation Analysis is negative, reflex to 1221*

**Candida**
- **Candida parapsilosis**
- **Candida lusitaniae**
- **Candida kefyr**
- **Candida albicans**
- **C. tropicalis**

**HPV**
- **190 HPV-16 & HPV-18 by Multiplex Real-Time PCR**
- **713 HPV Type-Detect 3.0 by Next Generation Sequencing (High Risk Subtypes Only)**
- **557 HPV Type-Detect 3.0 by Next Generation Sequencing**
- **558 HPV-16 & HPV-18 by Multiplex Real-Time PCR**
- **559 Candida glabrata by Real-Time PCR**
- **566 Candida krusei by Real-Time PCR**
- **551 Candida albicans by Real-Time PCR**
- **576 Candida dubliniensis by Real-Time PCR**
- **577 Candida lusitaniae by Real-Time PCR**
- **578 Candida kafy by Real-Time PCR**

**Urogenital Candidiasis Panel**
- **Mycoplasma genitalium**
- **UroSwab®**
- **& Thin-Prep UroSwab® both males & females**
- **Validated on UroSwab® both males & females**
- **Validated on UroSwab® both males & females**
- **Validated on UroSwab® both males & females**
- **Validated on UroSwab® both males & females**
- **Validated on UroSwab® both males & females**
- **Validated on UroSwab® both males & females**
- **Validated on UroSwab® both males & females**
- **Validated on UroSwab® both males & females**

**Recent Publications**

**Femiser Women’s Health Research Center:**


**Medical Diagnostic Laboratories, L.L.C.:**


**Oncoveda Cancer Research Center:**


**Metabolic Disorders Institute:**


**Abstracts (2015):**

**Venenum Biodesign:**


**Femiser Women’s Health Research Center (MDL):**


**Institute of Metabolic Disorders (MDL):**


**Question:**

I have a particular interest in one of the pathogens tested for by your laboratory.

**Answer:**

Through its multiple discipline integrated division-based scientific strategy, our Research and Development Department encourages and supports the creation of innovative projects in the fields of Microbiology, Women's Health and Gynecology, Pediatric Infectious Diseases, Cancer, Genetic Immunology, and Pharmacogenomics. This state-of-the-art research program promotes and fosters research collaborations and strategic partnerships with local, national and international Universities, Research Institutes and Biopharma companies. Please call 877.269.0090 for more information or visit our Research & Development page at www.mldlab.com/company/research-development.

If you have a question you would like addressed in future issues, please email your question(s) to QAQA@mdlab.com.